Skip to main content

Table 1 Characteristics of the study patients

From: Glycated hemoglobin and glycated albumin in patients with diabetes undergoing hemodiafiltration

Variable 
Number of patients (M/F)133 (81/52)
Age (years)68.7 ± 13.3
Dialysis history (months)78.3 ± 67.1
Dialysis time (h)3.7 ± 1.0
Blood flow rate (mL/min)204.7 ± 29.6
Dialysate flow rate (mL/min)531.8 ± 46.8
Replacement fluid volume (L)45.0 ± 14.8
Dry weight (kg)56.2 ± 14.1
Albumin (g/dL)3.4 ± 0.4
UN (mg/dL)60.6 ± 14.8
Hb (g/dL)10.6 ± 1.0
Ht (%)32.5 ± 3.2
Pre-dialysis blood glucose (mg/dL)138.4 ± 45.4
HbA1c (%)6.0 ± 0.9
GA (%)20.4 ± 4.7
Fe (μg/dL)59.7 ± 23.1
TIBC (μg/dL)206.3 ± 46.1
TSAT (%)30.0 ± 12.4
Ferritin (ng/dL)261.0 ± 187.6
ESAs
 Darbepoetin alfa (μg /week) (number)21.1 ± 17.4(98)
 epoetin beta (U/week) (number)3187.5 ± 1060.7(2)
 epoetin beta pegol (μg /week) (number)22.7 ± 9.8(11)
ERI (each ESA dose/kg/g/dL/week) 
 Darbepoetin alfa (number)0.04 ± 0.04(98)
 Epoetin beta (number)5.2 ± 1.5(2)
 Epoetin beta pegol (number)0.04 ± 0.02(11)
Iron (intravenous administration)
 Saccharated ferric oxide (mg/week) (number)44.2 ± 29.0(45)
Iron-based phosphate binder (oral administration)
 Sucroferric oxyhydroxide (mg/week) (number)8361.1 ± 5233.8(9)
 Ferric citrate hydrate (mg/week) (number)11940.3 ± 6267.9(22)
  1. TSAT(%) = [serum Fe (μg/dL)/TIBC (μg/dL)] × 100. The levels are presented as mean ± standard deviation